Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Overview of attention for article published in Clinical Cancer Research, June 2013

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 3 news outlets
twitter: 6 X users

patent: 5 patents
guideline: 6 clinical guideline sources

Readers on

mendeley: 228 Mendeley

So far, Altmetric has seen 8 X posts from 6 X users, with an upper bound of 22,142 followers.

RT @GladellPaner: @slusagar @Gleason4plus5 @FSiadat @Kiril_T_Can @priyaraomd @rajalbshah @SunnyKaoMD @Williamson_SR @SaraEWobker @daniel_be…

@slusagar @Gleason4plus5 @FSiadat @Kiril_T_Can @priyaraomd @rajalbshah @SunnyKaoMD @Williamson_SR @SaraEWobker @daniel_berney I think NE marker expression is a criterion for eligibility in clinical trials for castrate-resistant PCa (inc w/o NE morphology)…

Platinum-based chemotherapy for variant castrate-resistant prostate cancer. - PubMed - NCBI https://t.co/dTvsP6NXjE

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 4 additional X posts.